{"entity":{"id":"nct05969171","kind":"trial","name":"A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Ca","aka":[],"tldr":"A phase 2 trial of gemcitabine + nab-paclitaxel in pancreatic cancer, run by Fudan University, now recruiting.","summary":"A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer is a phase 2, interventional study registered as NCT05969171 by Fudan University, with a registry enrolment figure of 65 participants, started 2023-12-05 and due to reach its primary completion in 2026-12-31. Interventions recorded: Surufatinib, gemcitabine, nab-paclitaxel; Nab-paclitaxel, gemcitabine. Conditions listed: Pancreatic Cancer Metastatic. Primary outcome: Progression-free survival. Pancreatic eligibility wording from the registry: \"Unresectable, locally advanced or metastatic pancreatic cancer confirmed by histopathology or cytology;\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05969171","url":"https://clinicaltrials.gov/study/NCT05969171"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["gemcitabine-nab-paclitaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05969171","phase":"2","setting":"A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With Gemcitabine and Nab-paclitaxel or Gemcitabine Combined With Nab-paclitaxel in the First-line Treatment of Locally Advanced or Metastatic Pancreatic Cancer","sponsor":"Fudan University","enrolled":65,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05969171/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"gemcitabine-nab-paclitaxel","kind":"drug","name":"Gemcitabine + nab-paclitaxel","route":"/drugs/gemcitabine-nab-paclitaxel/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}